|
|
|
|
| LEADER |
01000naa a22002652 4500 |
| 001 |
NLM198809891 |
| 003 |
DE-627 |
| 005 |
20231223213429.0 |
| 007 |
cr uuu---uuuuu |
| 008 |
231223s2010 xx |||||o 00| ||eng c |
| 024 |
7 |
|
|a 10.1016/j.clim.2010.04.013
|2 doi
|
| 028 |
5 |
2 |
|a pubmed24n0663.xml
|
| 035 |
|
|
|a (DE-627)NLM198809891
|
| 035 |
|
|
|a (NLM)20547105
|
| 040 |
|
|
|a DE-627
|b ger
|c DE-627
|e rakwb
|
| 041 |
|
|
|a eng
|
| 100 |
1 |
|
|a Ray, Swagatam
|e verfasserin
|4 aut
|
| 245 |
1 |
0 |
|a MHC-I-restricted melanoma antigen specific TCR-engineered human CD4+ T cells exhibit multifunctional effector and helper responses, in vitro
|
| 264 |
|
1 |
|c 2010
|
| 336 |
|
|
|a Text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a ƒaComputermedien
|b c
|2 rdamedia
|
| 338 |
|
|
|a ƒa Online-Ressource
|b cr
|2 rdacarrier
|
| 500 |
|
|
|a Date Completed 30.08.2010
|
| 500 |
|
|
|a Date Revised 20.10.2021
|
| 500 |
|
|
|a published: Print-Electronic
|
| 500 |
|
|
|a Citation Status MEDLINE
|
| 520 |
|
|
|a Copyright 2010 Elsevier Inc. All rights reserved.
|
| 520 |
|
|
|a MHC class I-restricted human melanoma epitope MART-1(27-35) specific TCR-engineered CD4+CD25- T cells synthesize Th1 type cytokines and exhibit cytolytic effector function upon cognate stimulation. A detailed characterization of such TCR-engineered CD4+CD25- T cells now reveals that they are multifunctional. For example, they undergo multiple rounds of division, synthesize cytokines (IFN-gamma, TNF-alpha, IL-2, and MIP1ss), lyse target cells, and "help" the expansion of the MART-1(27-35) specific CD8+ T cells when stimulated by the MART-1(27-35) peptide pulsed DC. Multiparametric analyses reveal that a single TCR-engineered CD4+ T cell can perform as many as five different functions. Nearly 100% MART-1(27-35) specific TCR expressing CD4+ T cells can be generated through retroviral vector-based transduction and one round of in vitro stimulation by the peptide pulsed DC. MHC class I-restricted tumor epitope specific TCR transduced CD4+ T cells, therefore, could be useful in immunotherapeutic strategies for melanoma or other human malignancies
|
| 650 |
|
4 |
|a Journal Article
|
| 650 |
|
4 |
|a Research Support, U.S. Gov't, P.H.S.
|
| 650 |
|
7 |
|a Epitopes
|2 NLM
|
| 650 |
|
7 |
|a Histocompatibility Antigens Class I
|2 NLM
|
| 650 |
|
7 |
|a MART-1-Melan-A(27-35) epitope
|2 NLM
|
| 650 |
|
7 |
|a Neoplasm Proteins
|2 NLM
|
| 650 |
|
7 |
|a Receptors, Antigen, T-Cell
|2 NLM
|
| 700 |
1 |
|
|a Chhabra, Arvind
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Chakraborty, Nitya G
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Hegde, Upendra
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Dorsky, David I
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Chodon, Thinle
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a von Euw, Erika
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Comin-Anduix, Begonya
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Koya, Richard C
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Ribas, Antoni
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Economou, James S
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Rosenberg, Steven A
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Mukherji, Bijay
|e verfasserin
|4 aut
|
| 700 |
0 |
|
|a UCLA-CALTECH-CHLA-USC-UCONN Consortium on Translational Program in Engineered Immunity
|e verfasserin
|4 aut
|
| 773 |
0 |
8 |
|i Enthalten in
|t Clinical immunology (Orlando, Fla.)
|d 1999
|g 136(2010), 3 vom: 15. Sept., Seite 338-47
|w (DE-627)NLM098196855
|x 1521-7035
|7 nnns
|
| 773 |
1 |
8 |
|g volume:136
|g year:2010
|g number:3
|g day:15
|g month:09
|g pages:338-47
|
| 856 |
4 |
0 |
|u http://dx.doi.org/10.1016/j.clim.2010.04.013
|3 Volltext
|
| 912 |
|
|
|a GBV_USEFLAG_A
|
| 912 |
|
|
|a SYSFLAG_A
|
| 912 |
|
|
|a GBV_NLM
|
| 912 |
|
|
|a GBV_ILN_11
|
| 912 |
|
|
|a GBV_ILN_24
|
| 912 |
|
|
|a GBV_ILN_350
|
| 951 |
|
|
|a AR
|
| 952 |
|
|
|d 136
|j 2010
|e 3
|b 15
|c 09
|h 338-47
|